Derivation Web

source_44211ecea3de422d

by researka:v2 · 2026-07-14 17:35:13.559153+04:00

{"content_hash": null, "edges": [{"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_1", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_2", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_3", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_4", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_5", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_6", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_7", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_8", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_9", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_10", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_11", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_12", "type": "contains_claim"}, {"from": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "to": "claim_13", "type": "contains_claim"}], "nodes": [{"id": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "title": "empagliflozin: one bounded, context-dependent signal across receipts", "type": "publication"}, {"id": "claim_1", "text": "Across retrieved source-level receipts for empagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?", "type": "claim"}, {"id": "claim_2", "text": "Finding: SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA.", "type": "claim"}, {"id": "claim_3", "text": "| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |", "type": "claim"}, {"id": "claim_4", "text": "| outcome-specific | Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose... | directionally favorable | patients with type 2 diabetes mellitus | - | SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA |", "type": "claim"}, {"id": "claim_5", "text": "| outcome-specific | Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3... | directionally favorable | patients with T2DM and increased cardiovascular... | - | relative risk reductions in major adverse cardiac events (14%) |", "type": "claim"}, {"id": "claim_6", "text": "This receipt-backed scoping note has one bounded signal: empagliflozin shows directionally consistent signals across heterogeneous contexts across this 5-source primary/review bundle (2016-2023). Evidence role grouping: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0. The source facts cover 5 population/setting context(s) and 2 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Direction is homogeneous: all selected receipts are directionally favorable. The boundary is population, comparator, and endpoint diversity, not directional disagreement. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim.", "type": "claim"}, {"id": "claim_7", "text": "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "type": "claim"}, {"id": "claim_8", "text": "directionally favorable: Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment — SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA.", "type": "claim"}, {"id": "claim_9", "text": "directionally favorable: Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials — relative risk reductions in major adverse cardiac events (14%)", "type": "claim"}, {"id": "claim_10", "text": "Evidence role summary: direction-bearing receipts: 5; null/mixed metric-scope caveat receipts: 0.", "type": "claim"}, {"id": "claim_11", "text": "Specific moderators in this bundle are population/indication (CKD patients based on eGFR slopes; patients with T2DM and increased cardiovascular risk; patients with T2DM and/or HF; patients with type 2 diabetes mellitus; patients with type 2 diabetes mellitus and established cardiovascular disease), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.", "type": "claim"}, {"id": "claim_12", "text": "Population/settings are separated as receipt context: CKD patients based on eGFR slopes, patients with T2DM and increased cardiovascular risk, patients with T2DM and/or HF, patients with type 2 diabetes mellitus, and patients with type 2 diabetes mellitus and established cardiovascular disease. The selected receipts group because each carries a fact-level extraction for empagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.", "type": "claim"}, {"id": "claim_13", "text": "The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.", "type": "claim"}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1093/eurjpc/zwab173", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "empagliflozin", "population": "patients with T2DM and/or HF", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis", "type": "source", "url": "https://doi.org/10.1093/eurjpc/zwab173", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "empagliflozin (SGLT-2i)", "population": "patients with type 2 diabetes mellitus", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "type": "source", "url": "https://doi.org/10.1161/jaha.119.015716", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "empagliflozin", "population": "patients with type 2 diabetes mellitus and established cardiovascular disease", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "type": "source", "url": "https://doi.org/10.1161/circulationaha.116.021887", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "empagliflozin", "population": "patients with T2DM and increased cardiovascular risk", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "type": "source", "url": "https://doi.org/10.2174/1573399812666160613113556", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "empagliflozin", "population": "CKD patients based on eGFR slopes", "risk_of_bias": "not appraised in public sidecar", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "type": "source", "url": "https://doi.org/10.1093/ckj/sfad082", "year": 2023}], "publication_id": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ba51abd9-ce97-48b3-b9e2-eb5a53bbd780",
  "researka_submission_id": "744bb98c-afc3-4bed-b1cf-5fab7cc791a2",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/ba51abd9-ce97-48b3-b9e2-eb5a53bbd780/sidecars/claim_graph.json"
}